What is the program?
Verily and Dexcom are developing miniaturized continuous glucose monitors (CGM) to help people with Type 2 diabetes manage the condition. Verily and Dexcom are focused on minimizing the cost and size of CGM body-worn components, and providing connectivity to enable more people to control their diabetes with timely, actionable information.
How are you making it happen?
Traditional glucose monitoring methods are cumbersome and monitoring may be infrequent, but more data may provide valuable insights to help individuals better manage their own disease. Verily is building miniaturized sensor electronics on an adhesive patch to make continuous monitoring less disruptive. Over 380 million people around the world have diabetes, and those on insulin should check their glucose levels four times a day. Smaller and more comfortable CGMs may replace finger sticks in people with Type 2 diabetes, and have the potential to increase behavioral compliance and adherence to treatment regimens. The miniaturized patch is designed to enable continuous subcutaneous monitoring of the interstitial fluid that may be less burdensome for those required to measure their glucose levels. The patch will have wireless connectivity for secure data sharing and easy tracking of continuous glucose levels.Learn more in our newsroom